vs
Side-by-side financial comparison of Ares Commercial Real Estate Corp (ACRE) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $13.2M, roughly 1.4× Ares Commercial Real Estate Corp). Ares Commercial Real Estate Corp runs the higher net margin — -29.2% vs -90.7%, a 61.5% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -24.5%).
Ares Commercial Real Estate Corp is a specialty finance company focused on the commercial real estate sector. It offers a full suite of customized financing solutions including senior mortgage loans, subordinated debt and preferred equity, primarily serving middle-market commercial property owners and operators across the United States.
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
ACRE vs NAMS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.2M | $19.1M |
| Net Profit | $-3.9M | $-17.4M |
| Gross Margin | — | — |
| Operating Margin | -29.2% | -186.1% |
| Net Margin | -29.2% | -90.7% |
| Revenue YoY | -24.5% | 740.1% |
| Net Profit YoY | 63.8% | 55.5% |
| EPS (diluted) | — | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.2M | — | ||
| Q3 25 | $14.1M | — | ||
| Q2 25 | $12.6M | $19.1M | ||
| Q1 25 | $14.9M | — | ||
| Q4 24 | $17.5M | $12.8M | ||
| Q3 24 | $16.7M | $29.1M | ||
| Q2 24 | $16.8M | — | ||
| Q1 24 | $18.7M | — |
| Q4 25 | $-3.9M | — | ||
| Q3 25 | $4.7M | — | ||
| Q2 25 | $-11.0M | $-17.4M | ||
| Q1 25 | $9.3M | — | ||
| Q4 24 | $-10.7M | $-92.2M | ||
| Q3 24 | $-5.9M | $-16.6M | ||
| Q2 24 | $-6.1M | — | ||
| Q1 24 | $-12.3M | — |
| Q4 25 | -29.2% | — | ||
| Q3 25 | 33.0% | — | ||
| Q2 25 | -87.8% | -186.1% | ||
| Q1 25 | 64.4% | — | ||
| Q4 24 | -61.0% | -338.5% | ||
| Q3 24 | -35.3% | -85.9% | ||
| Q2 24 | -36.5% | — | ||
| Q1 24 | -65.9% | — |
| Q4 25 | -29.2% | — | ||
| Q3 25 | 33.0% | — | ||
| Q2 25 | -87.8% | -90.7% | ||
| Q1 25 | 62.5% | — | ||
| Q4 24 | -60.9% | -721.7% | ||
| Q3 24 | -35.3% | -57.2% | ||
| Q2 24 | -36.5% | — | ||
| Q1 24 | -65.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-0.15 | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-0.91 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $29.3M | $739.2M |
| Total DebtLower is stronger | $948.2M | — |
| Stockholders' EquityBook value | $509.6M | $778.5M |
| Total Assets | $1.6B | $815.1M |
| Debt / EquityLower = less leverage | 1.86× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.3M | — | ||
| Q3 25 | $84.9M | — | ||
| Q2 25 | $90.0M | $739.2M | ||
| Q1 25 | $125.5M | — | ||
| Q4 24 | $63.8M | $834.2M | ||
| Q3 24 | $68.9M | $422.7M | ||
| Q2 24 | $70.6M | — | ||
| Q1 24 | $99.5M | — |
| Q4 25 | $948.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $718.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $509.6M | — | ||
| Q3 25 | $521.0M | — | ||
| Q2 25 | $523.7M | $778.5M | ||
| Q1 25 | $542.1M | — | ||
| Q4 24 | $540.1M | $757.5M | ||
| Q3 24 | $563.8M | $378.9M | ||
| Q2 24 | $582.3M | — | ||
| Q1 24 | $601.1M | — |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | $815.1M | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.8B | $864.6M | ||
| Q3 24 | $1.9B | $439.2M | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.1B | — |
| Q4 25 | 1.86× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $21.4M | $-37.7M |
| Free Cash FlowOCF − Capex | — | $-37.8M |
| FCF MarginFCF / Revenue | — | -197.2% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.4M | — | ||
| Q3 25 | $3.8M | — | ||
| Q2 25 | $4.9M | $-37.7M | ||
| Q1 25 | $8.0M | — | ||
| Q4 24 | $35.5M | $-37.5M | ||
| Q3 24 | $8.4M | $-12.5M | ||
| Q2 24 | $8.7M | — | ||
| Q1 24 | $11.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-37.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.6M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -197.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -293.5% | ||
| Q3 24 | — | -43.2% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.82× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
